Skip to main content

Table 3 Results of ELISA using PM1-α peptide with polymyositis/scleroderma and various control sera

From: Clinical evaluation of autoantibodies to a novel PM/Scl peptide antigen

  Number (%) of anti-PM1-α-positive sera Mean value/standard deviation Top value
Polymyositis/scleroderma (n = 40) 22 (55) 3.1/3.2 11.6
Rheumatic disease controls (n = 452) 33 (7.3) 0.6/0.9 7.7
Polymyositis (n = 40) 3 (7.5) 1.0/1.1 7.4
Scleroderma (n = 205) 27 (13.2) 0.9/1.2 7.5
Rheumatoid arthritis (n = 69) 0 (0) 0.3/0.2 1.1
Mixed connective tissue disease (n = 6) 0 (0) 0.4/0.1 0.6
Undifferentiated connective tissue disease (n = 10) 0 (0) 0.3/0.0 0.4
Systemic lupus erythematosus (n = 114) 3 (2.6) 0.5/0.7 7.7
Other rheumatic diseases (n = 8) 0 (0) 0.3/0.1 0.6
Hepatitis C virus (n = 48) 2 (4.2) 0.5/0.5 2.6
Organ specific disorders (n = 23) 0 (0) 0.4/0.2 0.8
Hashimoto thyroiditis (n = 11) 0 (0) 0.3/0.2 0.8
Grave's disease (n = 12) 0 (0) 0.4/0.2 0.8
Healthy individuals (n = 4) 0 (0) 0.6/0.2 0.7